MindBio to develop the novel psilocin prodrug for neuropsychiatric indications utilizing microdosing to reduce or eliminate hallucinogenic impact of psychedelic...
NORTHAMPTON, MA / ACCESSWIRE / May 14, 2024 / Olivia Sloan was pursuing a career in health policy and research...
Lecture to focus on engineering strategies applied to design safe and efficacious bispecific drug candidates, utilizing our proprietary platform technologiesSEATTLE,...
The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net...
Announced positive survival data from ongoing randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancerPhase 2 topline...
PDAT clinical outcomes for infectious keratitis from Brazil and Mexico KNOXVILLE, TN, May 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals,...
Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase...
Cash runway extended into July 2025 from previously April 2025Capital raise strengthens Medigene’s financial positionLead program, MDG1015, on track for...
Expect to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite...
Agreement includes the discovery and enhancement of targeted oncology drug targets and biomarkers, in addition to positioning existing compoundsDURHAM, N.C.,...
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in...
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...
– Prostate segmentation using a deep learning convolutional neural network – – Model uses 24,611,072 parameters extracted from 7,466 training...
PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of...
Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American...
RESEARCH TRIANGLE PARK, N.C., May 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals Inc. (Nasdaq: BCRX) today announced that new data...
Scope of presentation included trial design, rationale, and blinded baseline data on first 50 patients randomized into the Phase II...
Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
Click here to register for May 14 investor webcastCompany plans to file its Earnings Report on May 14, 2024 on...